|
|
Frazier Healthcare Partners was founded in 1991 as one of the first healthcare-focused investment firms. The firm has partnered with entrepreneurs in all stages of company growth, from company creation and venture capital to growth buyouts and leveraged recapitalizations. Since raising its initial fund in 1991, Frazier Healthcare has raised nearly $4.2 billion from institutional funds and invested in more than 170 healthcare companies. The firm has financed several highly successful companies in the healthcare sector including Aspen Education Group, BARRX Medical, Bravo Health, Calistoga Pharmaceuticals, Calixa Pharmaceuticals, Cerexa, CHG Healthcare Services, Rigel, Threshold Pharmaceuticals, Tularik, XenoPort and Zeltiq Aesthetics. Of investments made through 2013, 30 have gone public and 57 have been sold in M&A transactions or through open market sales in the public markets. Frazier Healthcare Partners announced (November 2017) the closing of Frazier Life Sciences IX, L.P., exceeding its target and closing on nearly $419 million in capital commitments. The firm invests in profitable, lower middle-market healthcare companies with $10-75 million in EBITDA, and makes equity commitments ranging from $50-400 million.
|
